Recent publications from the Ting lab

June Brickey W, Felix NJ, Griffiths R, Zhang J, Wang B, Piskurich JF, Itoh-Lindstrom Y, Coffman TM, Ting JP.  Prolonged survival of class II transactivator-deficient cardiac allografts.  Transplantation. 2002 Nov 15;74(9):1341-8.

Chalermskulrat W, Neuringer IP, Brickey WJ, Felix NJ, Randell SH, Ting JP, Aris RM.  Hierarchical Contributions of Allorecognition Pathways in Chronic Lung Rejection.  Am J Respir Crit Care Med. 2002 Nov 21 [epub ahead of print]

Harton JA, Linhoff MW, Zhang J, Ting JP.  Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains.  J Immunol. 2002 Oct 15;169(8):4088-93.

Wong AW, Ghosh N, McKinnon KP, Reed W, Piskurich JF, Wright KL, Ting JP.  Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line.  J Immunol. 2002 Sep 15;169(6):3112-9.

van Deventer HW, Serody JS, McKinnon KP, Clements C, Brickey WJ, Ting JP.  Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors.  J Immunol. 2002 Aug 1;169(3):1634-9.

MacKeigan JP, Taxman DJ, Hunter D, Earp HS 3rd, Graves LM, Ting JP. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.  Clin Cancer Res. 2002 Jul;8(7):2091-9.

Ting JP, Trowsdale J.  Genetic control of MHC class II expression. Cell. 2002 Apr;109 Suppl:S21-33. Review.

Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis.  J Immunol. 2002 Apr 15;168(8):4173-83.

Felix NJ, de Serres S, Meyer AA, Ting JP.  Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection. J. Surg Res. 2002 Feb;102(2):185-92.

Arnett HA, Hellendall RP, Matsushima GK, Suzuki K, Laubach VE, Sherman P, Ting JP.  The protective role of nitric oxide in a neurotoxicant-induced demyelinating model.  J Immunol. 2002 Jan 1;168(1):427-33.

Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC.  Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity. 2001 Nov;15(5):787-99.

Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001 Nov;4(11):1116-22.

Zhu XS, Ting JP.  A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters.
Mol Cell Biol. 2001 Oct;21(20):7078-88.

Cressman DE, O'Connor WJ, Greer SF, Zhu XS, Ting JP.  Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator.
J Immunol. 2001 Oct 1;167(7):3626-34.

Harton JA, Zika E, Ting JP.  The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator.  J Biol Chem. 2001 Oct 19;276(42):38715-20.

Deffrennes V, Vedrenne J, Stolzenberg MC, Piskurich J, Barbieri G, Ting JP, Charron D, Alcaide-Loridan C. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.  J Immunol. 2001 Jul 1;167(1):98-106.

Li G, Harton JA, Zhu X, Ting JP.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.  Mol Cell Biol. 2001 Jul;21(14):4626-35.

Linhoff MW, Harton JA, Cressman DE, Martin BK, Ting JP.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.  Mol Cell Biol. 2001 May;21(9):3001-11.

Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K.  BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.  Nat Immunol. 2000 Dec;1(6):526-32.

Taxman DJ, Ting JP.  Identification of novel Mycoplasma hyorhinis gene fragments by differential display analysis of co-cultures.  J Microbiol Methods. 2001 Apr;44(3):217-23.

Saifuddin M, Roebuck KA, Chang Ch, Ting JP, Spear GT. Cutting edge: activation of HIV-1 transcription by the MHC class II transactivator.  J Immunol. 2000 Apr 15;164(8):3941-5.

MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000 Oct 18.

Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000 Sep;20(17):6185-94.

Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter.Mol Cell Biol. 2000 Aug;20(16):6051-61.

Taxman DJ, Cressman DE, Ting JP.  Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer. J Immunol. 2000 Aug 1;165(3):1410-6.

Felix NJ, Brickey WJ, Griffiths R, Zhang J, Van Kaer L, Coffman T, Ting JP.  H2-DMalpha(-/-) mice show the importance of major histocompatibility complex-bound peptide in cardiac allograft rejection.  J Exp Med. 2000 Jul 3;192(1):31-40.

Collins TS, Lee LF, Ting JP. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother. 2000 May;49(2):78-84.

Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP.  IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000 Mar 1;164(5):2769-75.

Ting JP, Zhu XS.  Class II MHC genes: a model gene regulatory system with great biologic consequences.
Microbes Infect. 1999 Sep;1(11):855-61. Review.

Brickey WJ, Wright KL, Zhu XS, Ting JP.  Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.
J Immunol. 1999 Dec 15;163(12):6622-30.

Ghosh N, Piskurich JF, Wright G, Hassani K, Ting JP, Wright KL. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem. 1999 Nov 5;274(45):32342-50.

Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JP.  Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J Neuroimmunol.1999 Oct 29;99(2):195-204.

Harton JA, Cressman DE, Chin KC, Der CJ, Ting JP.  GTP binding by class II transactivator: role in nuclear import. Science 1999 Aug 27;285(5432):1402-5.

Itoh-Lindstrom Y, Piskurich JF, Felix NJ, Wang Y, Brickey WJ, Platt JL, Koller BH, Ting JP.  Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J Immunol 1999 Sep 1;163(5):2425-31.

Martin BK, Frelinger JG, Ting JP.  Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol 1999 Jun 1;162(11):6663-70.

Cressman DE, Chin KC, Taxman DJ, Ting JP.  A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity 1999 Feb;10(2):163-71.

Piskurich JF, Linhoff MW, Wang Y, Ting JP.  Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta.  Mol Cell Biol 1999 Jan;19(1):431-40.

(click here for all of Jenny's publications since the beginning of time--okay, just 1980)